|
Gene: FAM114A1 |
Gene summary for FAM114A1 |
Gene summary. |
Gene information | Species | Human | Gene symbol | FAM114A1 | Gene ID | 92689 |
Gene name | family with sequence similarity 114 member A1 | |
Gene Alias | Noxp20 | |
Cytomap | 4p14 | |
Gene Type | protein-coding | GO ID | GO:0005575 | UniProtAcc | Q8IWE2 |
Top |
Malignant transformation analysis |
Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
Malignant transformation involving gene list. |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
92689 | FAM114A1 | P91T-E | Human | Esophagus | ESCC | 2.97e-07 | 1.18e+00 | 0.1828 |
92689 | FAM114A1 | P104T-E | Human | Esophagus | ESCC | 5.84e-05 | 5.87e-01 | 0.0931 |
92689 | FAM114A1 | P107T-E | Human | Esophagus | ESCC | 3.86e-32 | 8.58e-01 | 0.171 |
92689 | FAM114A1 | P126T-E | Human | Esophagus | ESCC | 1.01e-04 | 9.73e-01 | 0.1125 |
92689 | FAM114A1 | P127T-E | Human | Esophagus | ESCC | 2.95e-21 | 4.60e-01 | 0.0826 |
92689 | FAM114A1 | P128T-E | Human | Esophagus | ESCC | 4.97e-58 | 2.05e+00 | 0.1241 |
92689 | FAM114A1 | P130T-E | Human | Esophagus | ESCC | 2.69e-49 | 1.03e+00 | 0.1676 |
92689 | FAM114A1 | NAFLD1 | Human | Liver | NAFLD | 2.05e-05 | 5.74e-01 | -0.04 |
92689 | FAM114A1 | S43 | Human | Liver | Cirrhotic | 8.93e-07 | -4.85e-02 | -0.0187 |
92689 | FAM114A1 | HCC1_Meng | Human | Liver | HCC | 7.03e-58 | 4.55e-02 | 0.0246 |
92689 | FAM114A1 | HCC2_Meng | Human | Liver | HCC | 5.21e-28 | 2.30e-01 | 0.0107 |
92689 | FAM114A1 | HCC1 | Human | Liver | HCC | 2.67e-13 | 4.84e+00 | 0.5336 |
92689 | FAM114A1 | HCC2 | Human | Liver | HCC | 1.55e-08 | 4.12e+00 | 0.5341 |
92689 | FAM114A1 | Pt13.b | Human | Liver | HCC | 5.42e-05 | 1.60e-01 | 0.0251 |
92689 | FAM114A1 | S015 | Human | Liver | HCC | 1.95e-02 | 3.45e-01 | 0.2375 |
92689 | FAM114A1 | S027 | Human | Liver | HCC | 1.08e-15 | 1.47e+00 | 0.2446 |
92689 | FAM114A1 | S028 | Human | Liver | HCC | 4.62e-32 | 1.54e+00 | 0.2503 |
92689 | FAM114A1 | S029 | Human | Liver | HCC | 4.68e-23 | 1.58e+00 | 0.2581 |
92689 | FAM114A1 | C04 | Human | Oral cavity | OSCC | 1.32e-08 | 7.35e-01 | 0.2633 |
92689 | FAM114A1 | C21 | Human | Oral cavity | OSCC | 2.40e-50 | 1.56e+00 | 0.2678 |
Page: 1 2 3 4 5 6 7 |
Transcriptomic changes along malignancy continuum. |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
Figure of enriched GO biological processes. |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | |
Colorectum | SER | |
Colorectum | MSS | |
Colorectum | MSI-H | |
Colorectum | FAP |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
Enriched GO biological processes. |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
Page: 1 |
Enriched KEGG pathways. |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
Annotation of somatic variants for genes involved in malignant transformation |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
FAM114A1 | SNV | Missense_Mutation | c.19G>A | p.Asp7Asn | p.D7N | Q8IWE2 | protein_coding | tolerated_low_confidence(0.09) | benign(0.019) | TCGA-BH-A0DZ-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | docetaxel | SD | |
FAM114A1 | SNV | Missense_Mutation | c.713N>A | p.Thr238Asn | p.T238N | Q8IWE2 | protein_coding | deleterious(0) | possibly_damaging(0.554) | TCGA-E2-A15M-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | arimidex | SD | |
FAM114A1 | SNV | Missense_Mutation | c.547N>A | p.Glu183Lys | p.E183K | Q8IWE2 | protein_coding | tolerated(0.31) | benign(0.009) | TCGA-E2-A1IN-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | arimidex | SD | |
FAM114A1 | insertion | Frame_Shift_Ins | novel | c.512_513insCAGCCACTTTGGACCATCCGTAGGCT | p.Glu171AspfsTer10 | p.E171Dfs*10 | Q8IWE2 | protein_coding | TCGA-AO-A0JB-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | cyclophosphamide | SD | ||
FAM114A1 | deletion | Frame_Shift_Del | novel | c.782delN | p.Leu262CysfsTer5 | p.L262Cfs*5 | Q8IWE2 | protein_coding | TCGA-EW-A2FV-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | docetaxel | SD | ||
FAM114A1 | SNV | Missense_Mutation | novel | c.1240G>A | p.Glu414Lys | p.E414K | Q8IWE2 | protein_coding | tolerated(0.82) | benign(0.001) | TCGA-HM-A4S6-01 | Cervix | cervical & endocervical cancer | Female | <65 | III/IV | Chemotherapy | cisplatin | CR |
FAM114A1 | SNV | Missense_Mutation | c.1688C>T | p.Pro563Leu | p.P563L | Q8IWE2 | protein_coding | deleterious_low_confidence(0) | benign(0) | TCGA-VS-A9UD-01 | Cervix | cervical & endocervical cancer | Female | >=65 | III/IV | Chemotherapy | cisplatin | CR | |
FAM114A1 | SNV | Missense_Mutation | c.334N>A | p.Glu112Lys | p.E112K | Q8IWE2 | protein_coding | deleterious(0.05) | benign(0.197) | TCGA-AA-3977-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD | |
FAM114A1 | SNV | Missense_Mutation | rs143144596 | c.937N>A | p.Glu313Lys | p.E313K | Q8IWE2 | protein_coding | deleterious(0) | probably_damaging(0.978) | TCGA-AA-A00N-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | PD |
FAM114A1 | SNV | Missense_Mutation | rs149201693 | c.319N>A | p.Glu107Lys | p.E107K | Q8IWE2 | protein_coding | tolerated(0.05) | benign(0.263) | TCGA-AA-A010-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Chemotherapy | folinic | CR |
Page: 1 2 3 4 5 6 |
Top |
Related drugs of malignant transformation related genes |
Identification of chemicals and drugs interact with genes involved in malignant transfromation |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |